Author: Wang, Huihui; Song, Hyo; Pham, Anha V.; Cooper, Laurence J.; Schulze, Janika J.; Olek, Sven; Tran, Dat Q.
Title: Human LAP(+)GARP(+)FOXP3(+) regulatory T cells attenuate xenogeneic graft versus host disease Document date: 2019_4_12
ID: rudsvyqd_1
Snippet: FOXP3 + regulatory T cells (Tregs), a subset of CD4 + T cells, maintain immune homeostasis and prevent autoimmunity by suppressing auto-reactivity and regulating immune responses to foreign and self-antigens [1] . A hallmark of Tregs is their expression of the transcription factor, FOXP3, and the high level of CD25, the IL2 receptor alpha chain [2] . Due to their role in maintaining immune homeostasis and tolerance, Tregs have been considered as .....
Document: FOXP3 + regulatory T cells (Tregs), a subset of CD4 + T cells, maintain immune homeostasis and prevent autoimmunity by suppressing auto-reactivity and regulating immune responses to foreign and self-antigens [1] . A hallmark of Tregs is their expression of the transcription factor, FOXP3, and the high level of CD25, the IL2 receptor alpha chain [2] . Due to their role in maintaining immune homeostasis and tolerance, Tregs have been considered as potentially immunotherapy to prevent a variety of immunological diseases in human. Among potential diseases that may be tackled with such immune-modulators are most graft versus host disease (GVHD), a frequent and often severe complication following allogeneic hematopoietic cell transplantation [3] . Murine studies have demonstrated convincing evidence of the power of Tregs as a cell therapy to prevent and treat various Ivyspring International Publisher immunological conditions, such as multiple sclerosis, GVHD, inflammatory bowel disease and lupus [4] [5] [6] [7] [8] [9] [10] . In translating these studies to human therapeutic applications, one major limitation is the expansion of Tregs ex vivo to achieve consistently sufficient number and purity of bona fide Tregs. In the peripheral blood of healthy adults, there are ~5-10% FOXP3 + Tregs within total CD4 + T cells. Since FOXP3 is an intracellular transcription factor, only the CD4 + T cells with low CD127 and high CD25 expression, i.e., no more than 2-4% can be sorted to functionally isolate >90% FOXP3 purity. However, this population is not homogeneously Tregs, particularly in diseases where these markers are less correlative due to activated T cells. It has been established that there are two subsets of Tregs: those developed in the thymus (tTregs) and those generated in the periphery (pTregs). Moreover, naïve CD4 + T cells can be induced in vitro with TCR stimulation in the presence of TGFβ1 and IL2 to express FOXP3 (iTregs) [11] . The functional patterns for these different subgroups of Tregs are widely varying during the expansion of Tregs over a [3] [4] week period. In addition, the purity and composition of Tregs frequencies with respect to tTregs, iTregs, pTregs and CD4 + FOXP3 − nonTregs are also varying, resulting in an impure Treg product.
Search related documents:
Co phrase search for related documents- immune response and major limitation: 1, 2, 3, 4, 5, 6, 7, 8, 9
- immune response and multiple sclerosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- immune response and murine study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- immune response and peripheral blood: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- immune response and potential disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- immune response and self antigen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- immune response and TCR stimulation: 1, 2, 3
- immune response and therapeutic application: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- immune response and tolerance immune homeostasis: 1, 2, 3
- immune response and transcription factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- immune response and Tregs expansion: 1, 2, 3, 4
- immune response and Tregs frequency: 1
- immune response and week period: 1, 2, 3, 4, 5, 6, 7
- immune response regulate and inflammatory bowel disease: 1
- immune response regulate and multiple sclerosis: 1
- immune response regulate and peripheral blood: 1, 2
- immune response regulate and potential disease: 1
- immunological condition and peripheral blood: 1
- immunological disease and multiple sclerosis: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date